Sinopoulou Vasiliki, Groen Jip, Gordon Morris, Mougey Ed, Franciosi James P, de Meij Tim G J, Tabbers Merit M, Benninga Marc A
School of Medicine, University of Central Lancashire, Preston, UK.
Department of Pediatric Gastroenterology, Amsterdam University Medical Center, Amsterdam, Netherlands; Department of Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Center, Amsterdam, Netherlands; Reproduction and Development Research Institute, Amsterdam University Medical Center, Amsterdam, Netherlands.
Lancet Child Adolesc Health. 2025 May;9(5):315-324. doi: 10.1016/S2352-4642(25)00058-6.
Many treatments for abdominal pain-related disorders of gut-brain interaction (AP-DGBI) in children have been studied. We aimed to assess the efficacy and safety of all known treatment options for paediatric AP-DGBI.
For this systematic review and network meta-analysis, we searched Embase, MEDLINE, and CENTRAL databases from inception to Jan 16, 2025, for published randomised controlled trials. We included trials of any treatment for AP-DGBIs (irritable bowel syndrome, functional abdominal pain-not otherwise specified, and abdominal migraine, excluding functional dyspepsia) in children aged 4-18 years. We excluded randomised controlled trials that solely included children with functional dyspepsia, but we included studies in which children with functional dyspepsia were included alongside children with the other AP-DGBI diagnoses and outcome data could not be separated. Data extraction and quality appraisal were performed in duplicate. The primary outcome for this network meta-analysis was author-defined treatment success. Network meta-analysis methodology was used within a frequentist framework using multivariate meta-analysis and outcomes were assessed using the Grading of Recommendations, Assessment, Development and Evaluation methodology. Clinical relevance of effect sizes was interpreted according to consensus definitions.
Of 19 337 records identified through the database search, 155 records representing 91 original randomised controlled trials were included in the network meta-analysis: these 91 trials comprised 7226 participants (4119 females and 2673 males). 12 studies assessed dietary treatments (n=730), 25 assessed pharmacological treatments (n=2140), 23 assessed probiotic treatments (n=1762), and 35 assessed psychosocial treatments (n=2952). Two treatments were probably more effective for treatment success than control treatments (moderate certainty): hypnotherapy (risk ratio [RR] 4·99 [95% CI 2·15 to 11·57]; large effect size) and cognitive behavioural therapy (CBT; RR 1·99 [95% CI 1·33 to 2·98]; moderate effect size). All other treatments evaluated for treatment success were either not effective or the data were of very low certainty and thus no conclusions could be made.
Hypnotherapy and CBT show moderate certainty for treatment efficacy with clinically relevant effect sizes. No conclusions can be made about the other therapies and treatment success due to very low evidence certainty. Future randomised controlled trials should focus on improving the evidence certainty for those other therapies with regard to core AP-DGBI outcomes.
None.
针对儿童腹痛相关的肠-脑互动障碍(AP-DGBI)的多种治疗方法已得到研究。我们旨在评估所有已知的儿科AP-DGBI治疗方案的疗效和安全性。
对于这项系统评价和网状Meta分析,我们检索了Embase、MEDLINE和CENTRAL数据库,从数据库建立至2025年1月16日,以查找已发表的随机对照试验。我们纳入了针对4至18岁儿童AP-DGBI(肠易激综合征、功能性腹痛-未另作说明和腹型偏头痛,不包括功能性消化不良)的任何治疗的试验。我们排除了仅纳入功能性消化不良儿童的随机对照试验,但纳入了功能性消化不良儿童与其他AP-DGBI诊断儿童一起的研究,且结局数据无法分开的研究。数据提取和质量评估由两人独立进行。这项网状Meta分析的主要结局是作者定义的治疗成功。在频率学派框架内使用多变量Meta分析方法进行网状Meta分析,并使用推荐分级、评估、制定和评价方法评估结局。根据共识定义解释效应量的临床相关性。
通过数据库检索确定的19337条记录中,有155条记录代表91项原始随机对照试验被纳入网状Meta分析:这91项试验包括7226名参与者(4119名女性和2673名男性)。12项研究评估了饮食治疗(n = 730),25项评估了药物治疗(n = 2140),23项评估了益生菌治疗(n = 1762),35项评估了心理社会治疗(n = 2952)。两种治疗方法在治疗成功方面可能比对照治疗更有效(中等确定性):催眠疗法(风险比[RR]4.99[95%CI 2.15至11.57];大效应量)和认知行为疗法(CBT;RR 1.99[95%CI 1.33至2.98];中等效应量)。评估治疗成功的所有其他治疗方法要么无效,要么数据确定性非常低,因此无法得出结论。
催眠疗法和CBT在治疗疗效方面显示出中等确定性,且效应量具有临床相关性。由于证据确定性非常低,无法就其他疗法和治疗成功得出结论。未来的随机对照试验应侧重于提高这些其他疗法在核心AP-DGBI结局方面的证据确定性。
无。